Gastroenterology Unit, Azienda Ospedaliera Policlinico Tor Vergata, Rome, Italy.
Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Inflamm Bowel Dis. 2023 Oct 3;29(10):1555-1562. doi: 10.1093/ibd/izac242.
Recent retrospective studies have shown that frailty is common in hospitalized patients with inflammatory bowel disease (IBD) and enhances the risk of drug-related infections, postsurgery complications, hospital readmissions, and mortality, independently of age and comorbidities. We carried out a descriptive cohort study to evaluate the frequency of frail phenotype in IBD and analyzed the risk factors associated with this condition.
Frail phenotype was assessed in IBD patients by using the Fried frailty phenotype. Univariate and multivariate analyses were conducted to assess the risk factors for frail phenotype. Serum levels of interleukin (IL)-6 were quantified in patients with a frail or a fit phenotype by ELISA.
Three hundred eighty-six IBD outpatients (198 Crohn's disease and 188 ulcerative colitis) were prospectively enrolled from December 2021 to April 2022. Frail phenotype was diagnosed in 64 of 386 (17%) IBD patients and was significantly associated with female gender, active disease, and current use of steroids. Multivariate analysis showed that active disease was a risk factor for frail phenotype (odds ratio, 11.5; 95% confidence interval, 3.9-33.9). No difference in IL-6 serum levels was seen between patients with a frail phenotype and those who were fit.
This is the first prospective study showing that frail phenotype occurs in nearly one-fifth of IBD patients. Data indicate that active IBD is an independent risk factor for frail phenotype in IBD.
最近的回顾性研究表明，炎症性肠病（IBD）住院患者中普遍存在衰弱，且衰弱独立于年龄和合并症，会增加与药物相关的感染、手术后并发症、住院再入院和死亡的风险。我们进行了一项描述性队列研究，以评估 IBD 中衰弱表型的频率，并分析与该情况相关的危险因素。
使用 Fried 衰弱表型评估 IBD 患者的衰弱表型。进行单因素和多因素分析，以评估衰弱表型的危险因素。通过 ELISA 定量测定具有衰弱或健康表型的患者的血清白细胞介素（IL）-6 水平。
2021 年 12 月至 2022 年 4 月期间，前瞻性纳入了 386 名 IBD 门诊患者（198 名克罗恩病和 188 名溃疡性结肠炎）。386 名 IBD 患者中，64 名（17%）被诊断为衰弱表型，且该表型与女性、活动期疾病和当前使用类固醇显著相关。多因素分析显示，活动期疾病是衰弱表型的危险因素（比值比，11.5；95%置信区间，3.9-33.9）。衰弱表型患者和健康表型患者的血清 IL-6 水平无差异。
这是第一项前瞻性研究，表明衰弱表型发生在近五分之一的 IBD 患者中。数据表明，活动期 IBD 是 IBD 衰弱表型的独立危险因素。
